Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD'
Tweet Send to a Friend
Argus analyst Jasper Hellweg lowered the price target on Sanofi-Aventis (NASDAQ: SNY) to $55.00 (from $60.00) while maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
